Volume 139, Issue 5, Pages (November 2010)

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Advertisements

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Volume 131, Issue 2, Pages (August 2006)

Volume 149, Issue 6, Pages (November 2015)

Volume 146, Issue 2, Pages e6 (February 2014)

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B Emmet B. Keeffe, Stefan Zeuzem,

Volume 139, Issue 4, Pages (October 2010)

Volume 139, Issue 5, Pages e1 (November 2010)

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Boceprevir in Treatment Naive SPRINT-2

Volume 131, Issue 2, Pages (August 2006)

Volume 131, Issue 2, Pages (August 2006)

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Volume 139, Issue 4, Pages (October 2010)

Volume 153, Issue 4, Pages (October 2017)

Volume 143, Issue 3, Pages e5 (September 2012)

Peginterferon alfa-2b plus ribavirin for chronic hepatitis

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Volume 141, Issue 3, Pages e1 (September 2011)

Volume 138, Issue 2, Pages e1 (February 2010)

Volume 140, Issue 2, Pages e1 (February 2011)

Volume 150, Issue 4, Pages (April 2016)

Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B Emmet B. Keeffe, Stefan Zeuzem,

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse

Volume 155, Issue 5, Pages e2 (November 2018)

Volume 126, Issue 5, Pages (May 2004)

Volume 136, Issue 2, Pages e3 (February 2009)

Volume 141, Issue 5, Pages (November 2011)

Volume 146, Issue 2, Pages e6 (February 2014)

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening Brianna L. Norton,

Volume 146, Issue 7, Pages e3 (June 2014)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

Volume 152, Issue 1, Pages e4 (January 2017)

Volume 138, Issue 1, Pages (January 2010)

Volume 130, Issue 4, Pages (April 2006)

Volume 145, Issue 5, Pages e5 (November 2013)

Volume 142, Issue 6, Pages (May 2012)

Ingmar Mederacke, Michael P. Manns, Bernhard Meyer Gastroenterology

Volume 138, Issue 1, Pages e2 (January 2010)

Rafael Esteban, Maria Buti Gastroenterology

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease Markus.

Volume 145, Issue 4, Pages e3 (October 2013)

Recurrent Hematochezia in a Patient With Chronic Constipation

Volume 148, Issue 3, Pages (March 2015)

Volume 137, Issue 6, Pages (December 2009)

Genetic Factors and Hepatitis C Virus Infection

Volume 141, Issue 6, Pages (December 2011)

Volume 139, Issue 6, Pages (December 2010)

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

The Dawning of a New Editorial Board for Gastroenterology

Volume 136, Issue 5, Pages e2 (May 2009)

Volume 143, Issue 3, Pages e5 (September 2012)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Hepatitis C treatment in patients with kidney disease

This Month in Gastroenterology

Volume 132, Issue 1, Pages (January 2007)

Telaprevir in Treatment Experienced GT-1 PROVE3

Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels Mitchell L. Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert.

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Volume 135, Issue 2, Pages (August 2008)

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

Electronic Clinical Challenges and Images in GI

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Presentation transcript:

Volume 139, Issue 5, Pages 1593-1601 (November 2010) A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin Mark G. Swain, Ming–Yang Lai, Mitchell L. Shiffman, W. Graham E. Cooksley, Stefan Zeuzem, Douglas T. Dieterich, Armand Abergel, Mário G. Pessôa, Amy Lin, Andreas Tietz, Edward V. Connell, Moisés Diago Gastroenterology Volume 139, Issue 5, Pages 1593-1601 (November 2010) DOI: 10.1053/j.gastro.2010.07.009 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Randomized multicenter trials in which patients received peginterferon alfa-2a alone or in combination with ribavirin for the treatment of chronic hepatitis C. HVL, high viral load; RBV, ribavirin; tiw, three times weekly. Gastroenterology 2010 139, 1593-1601DOI: (10.1053/j.gastro.2010.07.009) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Patients negative for HCV RNA at last follow-up visit. SVR is defined as HCV RNA <50 IU/mL at the end of a 24-week follow-up phase. Gastroenterology 2010 139, 1593-1601DOI: (10.1053/j.gastro.2010.07.009) Copyright © 2010 AGA Institute Terms and Conditions